Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Share-based Compensation of $22.3 million for Q2 2026, up 675.65% year-over-year from $2.9 million in Q2 2025, and down 44.25% quarter-over-quarter from $40.0 million in Q1 2026.
Fulcrum Therapeutics (FULC) Share-based Compensation (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Share-based Compensation for 9 consecutive years, with $22.3 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Share-based Compensation rose 675.65% year-over-year to $22.3 million; the TTM figure through Jun 2026 stood at $22.3 million (up 80.77% YoY), while the FY2025 annual figure was $22.1 million, up 2.31% from the prior year.
- Share-based Compensation fell to $22.3 million in Q2 2026 per FULC's latest filing, from $40.0 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $40.0 million in Q1 2026 and bottomed at $2.5 million in Q4 2024.
- Historically, Share-based Compensation has averaged $7.6 million across 5 years, with a median of $3.6 million in 2023.
- Annual changes were most pronounced in 2025 — Share-based Compensation slumped 33.82% — and 2026, when it jumped 1163.02%.
- Fulcrum Therapeutics' Share-based Compensation stood at $3.3 million in 2022, then rose by 5.44% to $3.4 million in 2023, then decreased by 28.18% to $2.5 million in 2024, then rose by 23.78% to $3.1 million in 2025, then surged by 627.33% to $22.3 million in 2026.
- Business Quant data shows FULC's Share-based Compensation at $22.3 million in Q2 2026, $40.0 million in Q1 2026, and $3.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | 22.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.30 Mn |
| Jun 30, 2026 | 22.30 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | 3.07 Mn |
| Dec 31, 2025 | 3.07 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Sep 30, 2025 | 22.30 Mn |
| Jun 30, 2025 | 26.10 Mn |
| Jun 30, 2025 | 26.10 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Mar 31, 2025 | 3.17 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Dec 31, 2024 | 2.48 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Sep 30, 2024 | 3.82 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Jun 30, 2024 | 4.34 Mn |
| Mar 31, 2024 | 3.92 Mn |
| Mar 31, 2024 | 3.92 Mn |